Minerva Neurosciences (NERV)
NASDAQ:NERV
Want to see NERV full AI Analyst Report?
Top Page
Minerva Neurosciences
(NASDAQ:NERV)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▼(-33.14% Downside)
Action:Reiterated
Date:06/05/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, heavy cash burn, negative equity, and increased debt). Technical indicators also lean bearish with the stock below key moving averages and a negative MACD. Corporate events are a modest positive (governance updates and leadership refresh), while valuation is difficult to interpret due to negative earnings and no dividend support.
Positive Factors
Governance Strength
Updated charter and bylaws strengthen legal posture and shareholder mechanics, reducing procedural ambiguity and forum risk. Over the next several months this durable governance clarity can lower litigation and oversight friction, smoothing future financings, board actions, and strategic transactions.
Negative Factors
No Revenue / Persistent Losses
As a development‑stage biotech with no product revenue, profitability depends entirely on trial outcomes and external funding. Continued net losses increase dependency on capital markets and milestone partners, elevating execution and dilution risk and limiting runway absent successful clinical readouts.
Read all positive and negative factors
Positive Factors
Negative Factors
Governance Strength
Updated charter and bylaws strengthen legal posture and shareholder mechanics, reducing procedural ambiguity and forum risk. Over the next several months this durable governance clarity can lower litigation and oversight friction, smoothing future financings, board actions, and strategic transactions.
Read all positive factors
Minerva Neurosciences (NERV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$215.24M
Dividend YieldN/A
Average Volume (3M)465.60K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS Growth-3629.03%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-29.16
Shares Outstanding46,588,710
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$10.50Price Target Upside56.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.56
Revenue Forecast (FY)N/A
Minerva Neurosciences Business Overview & Revenue Model
Company Description
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfol...
How the Company Makes Money
Minerva Neurosciences has historically generated little to no recurring revenue from product sales because it has been primarily a development-stage company without widely commercialized products. Its funding has primarily come from financing acti...
Minerva Neurosciences Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
7
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -415.07M | -293.42M | 6.02M | -21.69M | -24.69M | -45.28M |
| Net Income | -415.07M | -293.42M | 1.44M | -30.01M | -32.11M | -49.91M |
Balance Sheet | ||||||
| Total Assets | 94.03M | 97.97M | 37.14M | 56.90M | 55.09M | 77.12M |
| Cash, Cash Equivalents and Short-Term Investments | 78.16M | 82.30M | 21.36M | 40.91M | 36.09M | 60.76M |
| Total Debt | 64.96M | 64.96M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 348.04M | 238.72M | 62.84M | 85.36M | 75.11M | 69.15M |
| Stockholders Equity | -254.01M | -140.75M | -25.69M | -28.46M | -20.02M | 7.98M |
Cash Flow | ||||||
| Free Cash Flow | -5.44B | -13.51B | -19.55M | -14.78M | -24.66M | -24.60M |
| Operating Cash Flow | -5.44B | -13.51B | -19.55M | -14.78M | -24.65M | -24.60M |
| Investing Cash Flow | -45.29B | 0.00 | 0.00 | 0.00 | -16.33K | 0.00 |
| Financing Cash Flow | 1.15B | 74.45B | 0.00 | 19.60M | -5.00 | 60.00M |
Minerva Neurosciences Technical Analysis
Negative
6.73
Price Trends
5.63
Negative
5.83
Negative
4.62
Negative
Market Momentum
-0.30
Negative
37.45
Neutral
27.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NERV, the sentiment is Negative. The current price of 6.73 is above the 20-day moving average (MA) of 4.92, above the 50-day MA of 5.63, and above the 200-day MA of 4.62, indicating a bearish trend. The MACD of -0.30 indicates Negative momentum. The RSI at 37.45 is Neutral, neither overbought nor oversold. The STOCH value of 27.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NERV.
Minerva Neurosciences Risk Analysis
Minerva Neurosciences disclosed 75 risk factors in its most recent earnings report. Minerva Neurosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Minerva Neurosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $12.82M | -1.77 | -89.92% | ― | ― | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.46M | -1.63 | -22.03% | ― | -93.71% | 23.89% | |
44 Neutral | $215.24M | -0.48 | 359.80% | ― | ― | -3629.03% | |
43 Neutral | $5.04M | -1.13 | -79.47% | ― | -100.00% | 62.88% |
* Healthcare Sector Average
NERV
Minerva Neurosciences
4.51
2.71
150.56%
BLRX
Bioline RX Ltd Sponsored ADR
3.37
-1.32
-28.14%
PULM
Pulmatrix
1.40
-6.41
-82.07%
CMMB
Chemomab Therapeutics
1.65
-3.15
-65.63%
ASBP
Aspire Biopharma Holdings
4.96
-433.64
-98.87%
Minerva Neurosciences Corporate Events
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting
Positive
Jun 4, 2026
On June 3, 2026, Minerva Neurosciences held its 2026 annual meeting of stockholders, where investors approved amendments to its certificate of incorporation to provide Delaware-permitted liability exculpation for certain officers and to remove an ...
Business Operations and StrategyPrivate Placements and Financing
Minerva Neurosciences Launches ATM Offering to Fund Trial
Neutral
May 27, 2026
On May 27, 2026, Minerva Neurosciences, Inc. entered into a sales agreement with Leerink Partners LLC to establish an at-the-market equity program allowing the company to issue and sell up to $75 million of its common stock from time to time. The ...
Regulatory Filings and ComplianceShareholder Meetings
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
Neutral
Apr 6, 2026
Minerva Neurosciences, Inc. announced that its 2026 annual meeting of stockholders is expected to be held on June 3, 2026, a date set more than 30 days before the one-year anniversary of its 2025 annual meeting, and has therefore adjusted its time...
Business Operations and StrategyExecutive/Board Changes
Minerva Neurosciences Appoints New Chief Business Officer, Counsel
Positive
Apr 2, 2026
On March 30, 2026, Minerva Neurosciences reached a settlement agreement with longtime executive Geoffrey Race, under which he resigned as president effective March 31, 2026, and stepped down as a director of subsidiary Mind-NRG. The package provid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.